Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Board Appointment - Oleg Nodelman appointed as Non-Executive Non-Independent Director to Galapagos' Board of Directors, effective October 7, 2024 [1] - Mr Nodelman replaces Dan G Baker who stepped down on October 6, 2024 [2] - Mr Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm [3] - Mr Nodelman holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University [4] Strategic Impact - The addition of Mr Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on the Forward, Faster strategy to accelerate innovation and create near-and long-term value [2] - Mr Nodelman's deep expertise in biotech and shared goals of unlocking further value for Galapagos will be instrumental in helping the company execute its near- and long-term strategy and deliver superior results for patients, shareholders, employees, and customers [3] - Mr Nodelman brings a wealth of experience in driving shareholder value, strategic transformations, and long-term growth initiatives [3] Company Overview - Galapagos is a biotechnology company with operations in Europe and the US dedicated to transforming patient outcomes through life-changing science and innovation [6] - The company focuses on high unmet medical needs and synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology [6] - Galapagos has capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, and the financial strength to invest strategically for the long-term [6]